A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis

OBJECTIVE: To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA). METHODS: Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients ≤ 18 years old with JoSpA not responding to...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgos-Vargas, Rubén, Loyola-Sanchez, Adalberto, Ramiro, Sofia, Reding-Bernal, Arturo, Alvarez-Hernandez, Everardo, van der Heijde, Desirée, Vázquez-Mellado, Janitzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358905/
https://www.ncbi.nlm.nih.gov/pubmed/35941676
http://dx.doi.org/10.1186/s13075-022-02877-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358905/
https://www.ncbi.nlm.nih.gov/pubmed/35941676
http://dx.doi.org/10.1186/s13075-022-02877-9

Ejemplares similares